Tumor mutational burden assessed by a targeted NGS assay predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer

被引：0
|
作者：
Jermann, P. [1 ]
Alborelli, I. [1 ]
Leonards, K. [1 ]
Rothschild, S. I. [2 ]
Leuenberger, L. [1 ]
Prince, S. Savic [1 ]
Mertz, K. [3 ]
Poechtrager, S. [3 ]
Zippelius, A. [2 ]
Quagliata, L. [4 ]
Bubendorf, L. [1 ]
机构：
[1] Univ Hosp Basel, Inst Pathol, Basel, Switzerland
[2] Univ Spital Basel, Basel, Switzerland
[3] Kantonsspital Liestal, Med Univ Klin, Liestal, Switzerland
[4] Univ Spital Basel, Pathol, Basel, Switzerland
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
161P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The predictive efficacy of tumor mutational burden for Immune Checkpoint Inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials
    Ying, M.
    Hu, M.
    Lei, Q.
    Weng, K.
    Zhou, W.
    ANNALS OF ONCOLOGY, 2024, 35
  • [32] Homologous Recombination Deficiency and Tumor Mutational Burden as Clinical Biomarkers for Non-Small Cell Lung Cancer
    Yip, James
    Lum, Christopher
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 1351 - 1352
  • [33] Homologous Recombination Deficiency and Tumor Mutational Burden as Clinical Biomarkers for Non-Small Cell Lung Cancer
    Yip, James
    Lum, Christopher
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 1351 - 1352
  • [34] Correlation between mutation burden of tumor and immunological/clinical parameters in considering biomarkers of immune checkpoint inhibitors for non-small cell lung cancer (NSCLC).
    Owada, Yuki
    Muto, Satoshi
    Takagi, Hironori
    Inoue, Takuya
    Watanabe, Yuzuru
    Yamaura, Takumi
    Fukuhara, Mitsuro
    Okabe, Naoyuki
    Matsumura, Yuki
    Hasegawa, Takeo
    Ohsugi, Jun
    Tanaka, Daisuke
    Ito, Emi
    Nanamiya, Hideaki
    Imai, Jun-ichi
    Isogai, Takao
    Watanabe, Shinya
    Suzuki, Hiroyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [35] Tumour Mutational Burden and Immune Checkpoint Inhibitor Response in Non-small Cell Lung Cancer: A Continuous Modelling Approach
    Sorich, Michael J.
    Manning-Bennett, Arkady T.
    Li, Lee X.
    Shahnam, Adel
    Kichenadasse, Ganessan
    Karapetis, Christos S.
    Abuhelwa, Ahmad Y.
    Mckinnon, Ross A.
    Rowland, Andrew
    Hopkins, Ashley M.
    TARGETED ONCOLOGY, 2025, : 361 - 369
  • [36] Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
    Qiu, Zhenbin
    Chen, Zihao
    Zhang, Chao
    Zhong, Wenzhao
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2019, 8 (01)
  • [37] Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer
    Bote, Helena
    Mesas, Andres
    Baena, Javier
    Herrera, Mercedes
    Paz-Ares, Luis
    EXPERT OPINION ON EMERGING DRUGS, 2022, 27 (03) : 289 - 300
  • [38] Immune Checkpoint Inhibitors in Oncogenic Driven Non-small Cell Lung Cancer
    Fonseca, A.
    Silva, E.
    Coutinho, D.
    Campainha, S.
    Dias, M.
    Barroso, A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S339 - S340
  • [39] Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors
    Soh, Junichi
    Hamada, Akira
    Fujino, Toshio
    Mitsudomi, Tetsuya
    CANCERS, 2021, 13 (16)
  • [40] Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Ushio, Ryota
    Murakami, Shuji
    Saito, Haruhiro
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (07)
12345